Loss of calbindin-28K immunoreactive neurones from the cortex in Alzheimer-type dementia.
An antibody raised against chick intestinal calbindin D28K was used to study the number and size of calbindin immunoreactive neurones in postmortem human brains from neurologically normal controls and from patients with neuropathologically diagnosed Alzheimer-type dementia (ATD). In the controls, calbindin immunoreactive neurones were observed in all cerebral cortex areas examined including the frontal, temporal and parietal cortices. When compared with the controls, the number and size of calbindin immunoreactive neurones were significantly reduced in the cortices of patients with ATD. These findings suggest that calbindin containing neurones are affected in ATD.
Ichimiya
Y
Y
MRC Group, AFRC Institute of Animal Physiology and Genetic Research, Babraham, Cambridge, U.K.
Emson
P C
PC
Mountjoy
C Q
CQ
Lawson
D E
DE
Heizmann
C W
CW
D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000378:metabolism* / Q000473:pathology; D064092:Calbindin 1; D064026:Calbindins; D002452:Cell Count; D002540:Cerebral Cortex / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D008970:Molecular Weight; D064030:S100 Calcium Binding Protein G / Q000378:metabolism*
C576498:CALB1 protein, human; D064092:Calbindin 1; D064026:Calbindins; D064030:S100 Calcium Binding Protein G